Zynlonta Safety Concerns Raise Regulatory Risk

Summary ADC Therapeutics announced a strategic reorganization that will reduce its workforce by approximately 17%, with resources redirected toward Zynlonta growth opportunities and regulatory priorities. The move follows safety concerns in LOTIS-5 and represents a meaningful negative signal for the company’s lymphoma ADC franchise. What…